Considering the well-known anti-angiogenic effect of IL-6 inhibition [20], and our own results demonstrating that tocilizumab inhibited tumor angiogenesis, it is possible that the anti-tumor effect of tocilizumab is mediated, at least in part, by decreased supply of oxygen and nutrients to tumor cells. The gene discussed is IL6; the disease is neoplasm.